|
|||||
|
|
CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment |
|
| Authors: | Artjoms Spaks Darja Svirina Irina Spaka Inta Jaunalksne Donats Breiva Ilmars Tracums |
| Institution: | 1. Department of Thoracic Surgery, Pauls Stradins Clinical University Hospital, Riga, Latvia;2. artjomsspaks@gmail.com;4. Department of Pathology, University of Latvia, Riga, Latvia;5. Department of Molecular Biology, Riga Stradins University, Riga, Latvia;6. Department of Clinical Immunology, Pauls Stradins Clinical University Hospital, Riga, Latvia |
| Abstract: | Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes.Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome. |
| Keywords: | Angiogenesis chemokines CXC chemokine ligand 4 non-small cell lung cancer platelet factor 4 |